By kpeuquet on August 12th, 2014

Today, PATH and Sanofi (Euronext: SAN and NYSE: SNY) announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa. The shipment signals a new era of lifesaving drugs made with safe, high-quality, and affordable artemisinin that is non-seasonal. By complementing botanically derived supplies, the new option can widen access to treatment for millions sickened by malaria every year—most of them young children in African countries.

Read the press release

Read PATH’s blog post: “A new era for malaria treatment”


New Antimalarial Treatments Produced with Semisynthetic Artemisinin